Clinical results of preoperative CDDP/5-FU chemotherapy followed by surgery for patients with clinical stage II/III thoracic esophageal cancer

The purpose of this study was to clarify the outcomes of preoperative CDDP/5-FU chemotherapy (FP therapy) followed by surgery for patients with clinical Stage II/III thoracic esophageal cancer. Seventeen patients with clinical Stage II/III thoracic esophageal cancer who underwent FP therapy followed...

Full description

Saved in:
Bibliographic Details
Published inFukuoka igaku zasshi = Hukuoka acta medica Vol. 104; no. 12; p. 523
Main Authors Kasagi, Yuta, Saeki, Hiroshi, Ando, Koji, Hiyoshi, Yukiharu, Ito, Shuhei, Sugimachi, Keishi, Yamashita, Yo-Ichi, Oki, Eiji, Uchiyama, Hideaki, Kawanaka, Hirofumi, Morita, Masaru, Ikeda, Tetsuo, Maehara, Yoshihiko
Format Journal Article
LanguageEnglish
Published Japan 25.12.2013
Subjects
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Chemotherapy, Adjuvant
Cisplatin - administration & dosage
Esophageal Neoplasms - drug therapy
Esophageal Neoplasms - pathology
Esophageal Neoplasms - surgery
Female
Fluorouracil - administration & dosage
Humans
Male
Middle Aged
Neoplasm Staging
Retrospective Studies
Treatment Outcome
Online AccessGet more information

Cover

More Information
Summary:The purpose of this study was to clarify the outcomes of preoperative CDDP/5-FU chemotherapy (FP therapy) followed by surgery for patients with clinical Stage II/III thoracic esophageal cancer. Seventeen patients with clinical Stage II/III thoracic esophageal cancer who underwent FP therapy followed by esophagectomy were investigated with regard to the perioperative clinical results and postoperative outcomes. Grade 3 or 4 adverse effects associated with FP therapy were recognized in 2 of the 17 (11.8%) cases, and 16 patients completed 2 cycles of FP therapy (94.1%). Complications after surgery occurred in 7 cases (41.2%). There were 7 patients with postoperative recurrences (41.2%), 6 of whom had clinical Stage III disease. Similarly, 4 out of the 5 patients who died of cancer had clinical Stage III disease. All recurrences and cancer-related deaths were recognized in histological effectiveness of Grade 0/1 cases. Preoperative FP therapy was found to be safe for patients with clinical Stage II/III thoracic esophageal cancer. However, the treatment seemed to be less beneficial for Stage III patients than for Stage II patients, thus suggesting that a more powerful preoperative treatment may be necessary for clinical Stage III patients.
ISSN:0016-254X